Colorectal cancer liver metastases: management and five-year survival in a South African patient cohort

M Brand,1,2 P Gaylard,3 J Ramos4

1 Department of Surgery, University of Pretoria, South Africa
2 School of Physiology, University of the Witwatersrand, South Africa
3 Data Management and Statistical Analysis, South Africa
4 WITS Donald Gordon Medical Centre; University of the Witwatersrand, South Africa

Corresponding author, email: rispah.chomba@wits.ac.za

Background: Approximately 25% of patients with colorectal cancer (CRC) will be diagnosed with CRC liver metastases (CRCLM) during the course of their disease. No data regarding CRCLM presentation, management and survival outcomes has been published from either the private or public health care sectors in South Africa. This study aimed to address this deficit, reporting on a private sector cohort.

Methods: A retrospective review of a private health care funder’s database from 1 January 2008 to 31 December 2015 was performed. ICD-10 diagnosis codes were used to identify CRC and CRCLM. Procedure codes assigned to hospital admissions were used to identify the type of surgical treatment. Chemotherapy was identified by the WHO Anatomical Therapeutic Chemical classification system of medicines. Treatment patterns were assessed and five-year overall survival (OS) was calculated. Survival was estimated using the Kaplan–Meier method, and Cox proportional-hazards regression was used for between group survival comparisons.

Results: Six hundred and one (601) of 3,412 patients presenting with CRC (17.6%) were diagnosed with CRCLM at presentation or during the follow-up period. Sixty patients with CRCLM (10.0%) underwent resection of the primary CRC and liver resection for metastases, 281 (46.8%) underwent CRC resection only, 180 (30%) received chemotherapy only, and 47 (7.8%) received no treatment. Five-year OS for these groups were 57.3%, 15.6%, 9.8%, and 0% respectively.

Conclusion: Five-year OS of the various CRCLM treatment pathways in a South African private sector population compares to results published in international series. However, a smaller proportion of patients with CRCLM underwent liver resection, compared to international studies.
was identified by the WHO Anatomical Therapeutic Chemical classification system of medicines. Patients were excluded if they were younger than 18 years old. Data on metastases at sites other than the liver were not collected and are therefore not considered in analyses.

Patients with liver metastases were assessed according to treatment group, with/without liver resection and with/without perioperative chemotherapy. Simultaneously detected metastases were defined as detected before or at the time of surgery for the primary tumour or within a month of diagnosis of the primary in non-operated patients. Date of withdrawal from the medical scheme was used as a surrogate for all-cause mortality and ongoing contribution to the scheme was interpreted as a patient still being alive.

**Statistical analysis**

Survival was estimated using the Kaplan–Meier method and Cox proportional-hazards regression was used for between group survival comparisons. A 5% significance level was used. Data analysis was performed on SAS version 9.4 for Windows (SAS Institute 2016).

**Results**

Of 3,412 patients with CRC, 601 (17.6%) were diagnosed with liver metastases during the study period. This group forms the basis of this study the treatment pathways of which are depicted in Figure 1. The median age of the CRCLM patients was 63 years (range 25–93 years) and 59.4% were males. Thirty-three patients (5.5%) were excluded due to incomplete data, i.e. the exact treatment could not be established. Of the remaining patients 60 (10.0%) underwent resection of the primary CRC and liver metastases, 281(46.8%) underwent CRC resection only, 180 (30.0%) received chemotherapy only and 47 (7.8%) received no treatment.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Number at inception</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRCLM resection</td>
<td>60</td>
</tr>
<tr>
<td>Chemotherapy only</td>
<td>392</td>
</tr>
<tr>
<td>No treatment</td>
<td>47</td>
</tr>
<tr>
<td>CRCLM metastases</td>
<td>601</td>
</tr>
<tr>
<td>CRCLM patients analysed</td>
<td>568</td>
</tr>
</tbody>
</table>

Figure 1: Summary of patient treatment pathways

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Number at inception</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant Chemotherapy (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>19</td>
</tr>
<tr>
<td>Adjuvant Chemotherapy (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>41</td>
</tr>
<tr>
<td>CRC Surgery - (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>224</td>
</tr>
<tr>
<td>CRC Surgery - (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>29</td>
</tr>
<tr>
<td>CRC Surgery - (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>28</td>
</tr>
<tr>
<td>CRC Surgery - (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>180</td>
</tr>
<tr>
<td>CRC Surgery - (Chemo) - CRC Surgery - (Chemo) - CRCLM Surgery – (Chemo)</td>
<td>47</td>
</tr>
</tbody>
</table>

Figure 2: Five year overall survival for various CRCLM treatment pathways
received no treatment. In patients that underwent resection of liver metastases, CRC resection was performed before liver resection in 56 (93.3%) and liver resection before the CRC resection in 4 (6.7%).

Combinations of folinic acid (FOL) and fluorouracil (F), irinotecan (IRI) and oxaliplatin (OX) were administered to 338 patients (56.1%). Of these, 50 (14.8%) underwent CRCLM resection, 23 (18.9%) following FOLFOX, 4 (4.8%) following FOLFIRI and 23 (17.3%) following FOLFIRINOX. The use of chemotherapy, regardless of regimen, combined with resection of CRCLM, significantly improved five-year OS compared to chemotherapy without resection of CRCLM (FOLFOX $p < 0.0001$, FOLFIRI $p = 0.033$ and FOLFOX and FOLFIRI $p = 0.014$).

Biologic agents (bevacizumab or cetuximab) with chemotherapy were used in 236 (46.6%) patients. However, their use was heterogenous and could not be included in the analyses. Five-year OS for no treatment, chemotherapy only and chemotherapy with surgical resection was 0%, 9.8% and 41–57% respectively. Survival data is presented in Figure 2 (Kaplan-Meier graph of overall survival per treatment cohort).

**Discussion**

The median overall survival of patients with untreated CRCLM is less than one year. With chemotherapy alone 1-year survival is 5–15% and following liver resection 5-year overall survival is 31–45%.

This audit of a South African private health care funder’s database demonstrates, similar to international trends, that 5-year OS for no treatment, chemotherapy only and chemotherapy with surgical resection is 0%, 10% and 41–57%. However, the overall incidence of CRCLM is lower than reported in international series. This may be due to underreporting of CRCLM, non-optimal follow-up or incomplete 5-year survival data. It also appears as if fewer CRCLM are treated surgically than in published series.

The survival estimates were capped at five years, beyond which there were too few patients at risk for reliable estimates. Resection of CRCLM has been shown to result in a significant improvement in 5-year OS of 55% compared to 15% with no resection. One of the most significant advances of CRCLM management has been the advent of modern cytotoxic agents that may result in conversion of irresectable into resectable disease. Liver resection following conversion chemotherapy therapy is associated with similar overall survival compared to resected initially resectable liver metastases. Modern treatment strategies now include neoadjuvant chemotherapy with or without monoclonal antibodies (biologic agents), sequential surgery, synchronous surgery of primary and liver metastases and the liver resection first approach.

In the reported patient cohort neoadjuvant chemotherapy resulted in a significant survival benefit compared to palliative chemotherapy without surgery. However, we cannot comment on the staging of disease in the chemotherapy only group. Overall, 5-year survival of surgical resection of the primary cancer and liver metastases followed by chemotherapy was similar to chemotherapy followed by surgical resection. The majority of synchronous disease was managed with a primary cancer resection preceding the CRCLM resection as a second procedure.

**Chemotherapy**

The probability that liver resection may offer long-term survival to patients with multiple CRCLM is higher in patients where the metastatic disease is controlled by neoadjuvant chemotherapy prior to surgery. Five-year OS in patients who underwent liver resection following neoadjuvant chemotherapy with an objective tumour response compared to stable disease, or tumour progression was 37%, 30% and 8% respectively. The type of neoadjuvant chemotherapy agents used does not influence the outcomes provided that complete resection of all liver metastases is achieved. However, the shorter the course of neoadjuvant chemotherapy and the fewer the number of chemotherapy lines administered, the lower the postoperative morbidity and longer overall survival. The threshold appears to be five cycles. Our data indicates that with both FOLFOX and FOLFIRI chemotherapy, the survival of those who received surgical resection of either the primary CRC with or without CRCLM resection was better than those who did not. There was no significant difference in overall survival with the use of either FOLFOX or FOLFIRI.

**Biologics**

Chemotherapy with molecular target agents has provided further improvement in tumour response rates. The value of biologic agents in relation to liver resection seems to be in the neoadjuvant setting, as chemotherapy with the addition of bevacizumab has been shown to have no impact on either recurrence free survival or overall survival in the adjuvant setting following complete resection of colorectal liver metastases. This tendency is seen in the presented data. However, the routine use of neoadjuvant chemotherapy-biologic agent is controversial, and guidelines currently only recommend this combination for conversion therapy. The concurrent use of bevacizumab with oxaliplatin-based chemotherapy as a first-line therapy did not result in a significantly increased response rate or resection rate of liver metastases; more recent studies have demonstrated a response rate of 30–81% in anti-VEGF treated CRCLM patients, similar to the 30–73% in chemotherapy only treated patients (including quadruple chemotherapy regimens).

**Multidisciplinary team assessment**

In patients with CRC tumor the most important factor that affects patient prognosis is the resectability of the metastatic lesions. As a result of the increasing complexity of CRCLM management, patients are often undertreated unless a liver surgeon is involved early in the decision-making process. Discussion in a multidisciplinary team (MDT) composed of appropriate specialists as early as possible in a patient’s management algorithm is crucial. A Swedish study, where MDT discussion is a national requirement for each patient with CRC, showed that when no liver surgeons were on these teams only 17.8% of liver metastases were resected, a percentage below international norms. A British study compared the treatment decisions determined initially by non-liver surgeons and compared them to liver surgeons’ opinions; the liver surgeons felt that 63% of the cases deemed not resectable by the MDT were resectable. An American study found that referral to a liver surgeon was associated with a 5-year OS of 33% compared with 8% in patients who were not. Hence, patients with CRCLM that are managed without the involvement of a specialist liver
MDT may lead to some patients being denied potentially curative treatments. This study was not able to determine whether or not South African CRCLM patients are routinely discussed in an MDT; however, from international literature MDTs should be the norm for these patients.

There are limitations in this study. Data was retrieved from a single private health care funder’s database that represents 53% of South Africans with health insurance. The database is primarily designed for health economic data capture with limited clinical information, thus study results are based on treatments claimed from the medical scheme. In other words, treatments that members did not claim from the scheme are not included. Examples may include treatment received as part of a clinical trial, self-funded medication or treatment received from state facilities. Furthermore, access to certain treatment modalities is dependent on the patient’s medical aid plan, for example access to biologic medications is not available to all patients. As a result of the paucity of clinical information, only treatment patterns are reported. Follow-up in some patients was only one year which may have resulted in under-reporting of CRCLMs. Differences observed in the reported cohort compared to international studies are more likely the result of incomplete data than the disease being different in South African patients. The results of this study cannot be extrapolated into the public health care sector as the treatment of the disease seemingly differs significantly with regards to disease presentation as well as access to treatment such as chemotherapy and biologic agents. The survival estimates and Kaplan–Meier plot are limited by the fact that a surrogate for all-cause mortality derived from secondary medical aid administrative data and not primary clinical data was used. Therefore, we could not adjust for covariates and there may be missing information. Furthermore, not accounting for patients with extrahepatic metastases is an additional shortcoming in the study.

Conclusion
We have demonstrated that 5-year OS is improved with the use of chemotherapy and better following surgical resection of CRCLM compared to chemotherapy alone. All patients with CRCLM should be managed in an MDT, either with neoadjuvant or adjuvant chemotherapy. The use of biologic agents without CRCLM resection does not seem to improve overall survival.

Acknowledgements
Discovery Health, specifically the Clinical Policy Unit, for their assistance with data extraction and management.

Conflict of interest
The authors declare no conflict of interest.

Funding source
Wits Donald Gordon Medical Centre, University of the Witwatersrand, for funding the statistical analysis of the data.

Ethical approval
Ethics approval was granted by the University of the Witwatersrand Human Research Ethics Committee (M141027).

REFERENCES

ORCID
M Brand https://orcid.org/0000-0001-8285-3880
P Gaylard https://orcid.org/0000-0002-0055-9168
J Ramos https://orcid.org/0000-0003-1341-7684


